We are live on
!
Find out more
Alyeska Investment Group Portfolio holdings
AUM
$35.4B
1-Year Est. Return
33.54%
This Fund
S&P 500
This Quarter
Est. Return
+3.53%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.33%
AUM
$12B
AUM Growth
-$353M
(-2.9%)
Cap. Flow
-$617M
Cap. Flow
% of AUM
-5.16%
Top 10 Holdings %
Top 10 Hldgs %
12.46%
Holding
637
New
171
Increased
105
Reduced
150
Closed
191
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delta Air Lines
DAL
|
+$140M |
| 2 |
AbbVie
ABBV
|
+$119M |
| 3 |
KeyCorp
KEY
|
+$115M |
| 4 |
F5
FFIV
|
+$111M |
| 5 |
Walmart Inc
WMT
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$146M |
| 2 |
S&P Global
SPGI
|
+$142M |
| 3 |
Eli Lilly
LLY
|
+$133M |
| 4 |
Labcorp
LH
|
+$131M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$121M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.86% |
| 2 | Healthcare | 13.19% |
| 3 | Industrials | 12.91% |
| 4 | Consumer Discretionary | 10.27% |
| 5 | Financials | 9.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Zevra Therapeutics
ZVRA
$620M
| $3.9M | 0.03% |
60,914
-1,347
| -2% | -$88.7K |
|
|
PRTK
302
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $3.85M | 0.03% |
+159,814
| New | +$3.53M |
|
303
Illinois Tool Works
ITW
$85.2B
| $3.84M | 0.03% |
+26,776
| New | +$3.73M |
|
304
Meta Platforms (Facebook)
META
$1.49T
| $3.77M | 0.03% |
24,951
-193,088
| -89% | -$28.7M |
|
|
BHVN
305
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.74M | 0.03% |
+149,651
| New | +$3.45M |
|
|
GMS
306
DELISTED
GMS Inc
GMS
| $3.72M | 0.03% |
+132,387
| New | +$4.44M |
|
|
MSCC
307
DELISTED
Microsemi Corp
MSCC
| $3.68M | 0.03% |
+78,593
| New | +$3.85M |
|
308
GDS Holdings
GDS
$6.61B
| $3.67M | 0.03% |
395,698
-235,080
| -37% | -$1.9M |
|
|
EXPR
309
DELISTED
Express, Inc.
EXPR
| $3.38M | 0.03% |
+25,000
| New | +$3.88M |
|
|
310
Oracle
ORCL
$417B
| $3.32M | 0.03% |
66,128
-3,204,010
| -98% | -$146M |
|
|
ILG
311
CALL
DELISTED
ILG, Inc Common Stock
ILG
| $3.27M | 0.03% |
+119,000
| New | +$3.01M |
|
312
Stanley Black & Decker
SWK
$15.6B
| $3.17M | 0.03% |
+22,543
| New | +$3.09M |
|
|
AERI
313
DELISTED
Aerie Pharmaceuticals
AERI
| $3.15M | 0.03% |
60,000
+33,442
| +126% | +$1.56M |
|
|
BHI
314
DELISTED
Baker Hughes
BHI
| $3.08M | 0.03% |
+56,561
| New | +$3.25M |
|
|
SGBK
315
DELISTED
Stonegate Bank
SGBK
| $3.08M | 0.03% |
+66,596
| New | +$3.05M |
|
316
Aon
AON
$76.2B
| $3.05M | 0.03% |
+22,930
| New | +$2.9M |
|
317
Xylem
XYL
$28.4B
| $3.02M | 0.03% |
54,506
-36,813
| -40% | -$1.92M |
|
318
Ramaco Resources Class A
METC
$624M
| $2.87M | 0.02% |
490,956
+77,520
| +19% | +$504K |
|
|
ATYR
319
aTyr Pharma
ATYR
$51M
| $2.85M | 0.02% |
59,947
+2,115
| +4% | +$99K |
|
320
Upland Software
UPLD
$13.2M
| $2.75M | 0.02% |
+12,500
| New | +$2.55M |
|
|
321
Labcorp
LH
$25.4B
| $2.74M | 0.02% |
20,719
-1,070,408
| -98% | -$131M |
|
|
FSTX
322
CALL
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $2.71M | 0.02% |
50,000
| – | – |
|
323
Accenture
ACN
$104B
| $2.62M | 0.02% |
+21,198
| New | +$2.58M |
|
|
CSLT
324
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $2.59M | 0.02% |
623,547
-18,895
| -3% | -$73.7K |
|
325
CALL
TETRA Technologies
TTI
$1.26B
| $2.58M | 0.02% |
925,000
| – | – |
|
Similar funds
SAM
VIA
Alyeska Investment Group's Q2 2017 Portfolio in Review
As of Q2 2017, Alyeska Investment Group held 637 positions worth $12B, down 2.9% from $12.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Alyeska Investment Group withdrew a net $617M in Q2 2017, closing 191 positions and reducing 150 holdings. Its most notable exit was Eli Lilly, an estimated $133M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 14% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Alyeska Investment Group opened a new position in AbbVie worth $128M.
- Alyeska Investment Group's largest Q2 2017 buy was AbbVie: 1,771,895 shares worth $128M.
- Alyeska Investment Group added most to Delta Air Lines in Q2 2017, an estimated $140M increase.
- Alyeska Investment Group's biggest Q2 2017 reduction was Oracle, cutting an estimated $146M.
- Alyeska Investment Group fully exited Eli Lilly in Q2 2017, selling an estimated $133M.
- Alyeska Investment Group's ten largest holdings make up 12% of its $12B portfolio in Q2 2017.
- Alyeska Investment Group opened 171 new positions and closed 191 in Q2 2017.
- Alyeska Investment Group's portfolio value fell 2.9% quarter-over-quarter to $12B.
Based on Alyeska Investment Group's 13F filing for Q2 2017, filed 14 Aug 2017.